Oxytocin Add-on for Stable Depressed Patients

Major Depressive Disorder Clinical Trial

Official title:

Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antidepressant Medication in Depressed Patients.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01211756
• Other study ID #: Oxytocin Depression
• Status: Terminated
• Phase: N/A
• Start date: October 2010
• Est. completion date: December 2015

Study information

• Verified date: December 2016
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve depression symptoms in patients with Major Depressive Disorder (MDD) or Dysthymia Disorder.

Description:

Depression patients treated with even the best currently available antidepressant drugs continue to experience significant symptoms. There is a strong need for better treatments including treatments that can safely be given adjunctively with concurrent antidepressants in order to improve overall efficacy of treatment.

Oxytocin is a neurohypophyseal peptide best known for its role as a neurohormone involved in parturition and lactation. In addition to these well established peripheral effects, there is a compelling body of converging evidence indicating that oxytocin plays a critical role in the regulation of a number of diverse centrally-mediated behavioral and cognitive processes that are highly relevant to mood regulation and mood disorders, including social attachment (Argiolas and Gessa 1990; McCarthy and Aaltemus 1997).

Each subject will be enrolled for a 8 week treatment period after a screening phase. Study procedure involves weekly clinic visits as an outpatient. Twenty patients will be randomly assigned to either 40 IU oxytocin twice daily or vehicle placebo. After 4 weeks, treatments will be crossed over such that subjects that received oxytocin will receive placebo and vice versa. The study ratio is 1:1. Dose of oxytocin is based upon previous studies in humans showing improvement in psychiatric populations related changes in behavior and brain function (Kosfeld et al, 2005; Kirsch 2005; Heinrich M 2003).

The total study duration for each individual subject will be approximately 9 weeks, which includes up to 31-day screening period, a baseline (randomization) visit, four week treatment period, 1 week washout, baseline 2 visit, and four weeks cross over treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: December 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult men or women, 18 years of age or older.

2. Meet DSM-IV criteria for Major Depressive Disorder or Dysthymia Disorder

3. Women of childbearing potential must test negative for pregnancy at the time of enrollment based on urine pregnancy test and agree to use a reliable method of birth control during the study.

4. Must be on a therapeutic dose of 1 or 2 antidepressants with no major dose changes for at least 4 weeks at randomization.

5. MADRS score of >17 at randomization

6. Have a Clinical Global Impressions-Severity (CGI-S) scale score of at least 4 (moderately ill) at baseline.

7. Must be able to communicate effectively with the investigator and study coordinator and have the ability to provide informed consent.

8. Must be able to use nasal spray

9. Must demonstrate an acceptable degree of compliance with medication and procedures in the opinion of the investigator. (If patient cannot then he/she will be considered for the acute only portion of this study.)

Permitted:

Subjects on up to 2 sleep medication (diphenhydramine, zolpidem, zaleplon, or diazepam), at a reasonable dose, as judged by the investigator, is permitted in this study.

Minor adjustments in sleep medication is acceptable. Patients will be asked to notify the study doctor of any changes to sleep aids.

Exclusion Criteria:

Subjects will be excluded from the study of they meet any of the following criteria:

1. Are pregnant or are breastfeeding (negative pregnancy test at screening)

2. A urine drug screen performed at screening must not show evidence of recent use of drugs of abuse

3. Any active medical condition that in the opinion of the investigator will interfere with the objectives of the study

4. Are unsuitable in any way to participate in this study, in the opinion of the investigator.

5. Another current DSM-IV diagnosis other than Major Depressive Disorder or Dysthymia Disorder

Related Conditions & MeSH terms

• Depressive Disorder
• Depressive Disorder, Major
• Disease
• Dysthymia Disorder
• Major Depressive Disorder

Intervention

Drug:
• Oxytocin
20 IU BID for one week, followed by 40 IU BID for 3 weeks.
• Placebo
20 IU BID for one week, followed by 40 IU BID for 3 weeks.

Locations

Country	Name	City	State
United States	UCSD Medical Center	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
David Feifel

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Score on Montgomery-Asberg Depression Rating Score (MADRS)	The MADRS is a clinician-rated assessment used to measure the severity of depressive episodes in patients with mood disorders. The measure contains 10 items and each item is scored in a range of 0 to 6 points, with higher score indicating increased depressive symptoms.	Performed at each visit (weekly)
Secondary	Global Assessment of Functioning (GAF)	The GAF considers psychological, social, and occupational functioning on a hypothetical continuum of mental health illness. Scores on the GAF range from 1 (extremely severe) to 100 (superior functioning).	Performed at each visit (weekly)
Secondary	Clinical Global Impression-Severity of Illness (CGI-S)	The CGI-S is used to evaluate changes in overall severity of illness. Scores on the CGI-S range from 1 (not at all) to 7(among the most extremely ill).	Performed at each visit (weekly)
Secondary	Clinical Global Impression-Global Improvement (CGI-I)	The CGI-I is a global assessment to evaluate the subjects' improvement or worsening from baseline. Scores on the CGI-I scale range from 1 (very much improved) to 7 (very much worse).	Performed at each visit (weekly)
Secondary	Young Mania Rating Scale (YMRS)	The YMRS is an 11-item assessment used to assess the severity of mania in patients with a diagnosis of bipolar disorder. Ratings are based on patient self-reporting, combined with clinician observed.	Performed at each visit (weekly)
Secondary	Hamilton-Anxiety Scale (HAM-A)	The HAM-A is a clinician administered scale for the evaluation of anxiety symptoms. The HAM-A consists of 14 items of which each item is scored 0 (not present) to 4 (very severe).	Performed at each visit (weekly)
Secondary	Reading Trust in the Mind's Eye Test	The subject will view approximately 16 faces and asked to rate trustfulness of the person in the picture.	Performed at the beginning and end of each treatment arm.
Secondary	Profile of Mood States (POMS)	The POMS is a self-rated scale to assess current mood states. The POMS consists of 65 words that the subject will rate from 1 (not at all) to 5 (extremely) based on how he/she feels at the time.	Performed at the beginning and end of each treatment arm
Secondary	Arizona Sexual Experience Scale (ASEX)	The ASEX is a self-rated scale to assess sexual functioning. The ASEX consists of 5 items that the subject will rate from 1 (Extremely strong, easily, or satisfying) to 6 (Absent or never) based on how he/she feels at the time.	Performed at each visit (weekly)
Secondary	Peabody Picture Vocabulary Test	The subject is read a series of words and is shown line drawings and is asked to match the word to the drawing.	Performed at the beginning of the study
Secondary	California Verbal Learning Test	The subject is read a list of words and asked to repeat them back first after the list is read and again 20 minutes later.	Performed at the beginning and end of each treatment arm
Secondary	Letter Number Sequencing Memory Test	The examinee is read a combination of numbers and letters and is asked to recall the numbers first in ascending order and then the letters in alphabetical order. Each item consists of three trials, and each trial is a different combination of numbers and letters.	Performed at the beginning and end of each treatment arm
Secondary	Continuous Performance Test (CPT)	Patients are told that they will see a series of letters presented on a screen. They are told to click a computer mouse only when they see the "target" stimulus, for instance the letter "X", and must refrain from clicking if they see any other letter presented.	Performed at the beginning and end of each treatment arm